Suppr超能文献

完整人多形核白细胞上特异性C5a受体的证实。

Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes.

作者信息

Chenoweth D E, Hugli T E

出版信息

Proc Natl Acad Sci U S A. 1978 Aug;75(8):3943-7. doi: 10.1073/pnas.75.8.3943.

Abstract

Human C5a, a complement-derived anaphylatoxin, is a potent mediator of human leukocyte chemotaxis. Using a homogeneous preparation of C5a that was 125I-labeled, we have demonstrated the presence of a specific cellular receptor for this glycoprotein on intact human polymorphonuclear leukocytes. Cellular uptake of the radiolabeled ligand occurred rapidly and the rate of dissociation was extremely slow. Cellular binding was saturable with respect to 125I-labeled C5a, and half-saturation occurred at a concentration of 3-7 X 10(-9) M. The number of C5a binding sites per cell was estimated as 1-3 X 10(5). The ligand (C5a) displays specific structural features that are required for binding because analogs of C5a such as C5ades Arg or a yeast carboxypeptidase-digested C5a derivative C5a-(I-69) inhibited the binding but C3a anaphylatoxin, which resembles C5a chemically, did not. Both C5a-mediated leukocyte chemotaxis and C5a-induced lysosomal enzyme release from cytochalasin B-treated cells closely paralleled uptake of the ligand, clearly indicating that it is a receptor-C5a interaction that leads to stimulation of these cellular responses.

摘要

人C5a是一种补体衍生的过敏毒素,是人类白细胞趋化性的有效介质。我们使用125I标记的纯C5a制剂,证明了完整的人类多形核白细胞上存在这种糖蛋白的特异性细胞受体。放射性标记配体的细胞摄取迅速,解离速率极慢。就125I标记的C5a而言,细胞结合是可饱和的,半饱和发生在3 - 7×10(-9) M的浓度下。每个细胞的C5a结合位点数量估计为1 - 3×10(5)。配体(C5a)显示出结合所需的特定结构特征,因为C5a的类似物如C5ades Arg或酵母羧肽酶消化的C5a衍生物C5a-(I - 69)抑制结合,但化学上类似于C5a的C3a过敏毒素则没有。C5a介导的白细胞趋化性和C5a诱导的细胞松弛素B处理细胞的溶酶体酶释放都与配体的摄取密切平行,清楚地表明是受体 - C5a相互作用导致了这些细胞反应的刺激。

相似文献

引用本文的文献

3
The Role of Complement Dysregulation in Glaucoma.补体失调在青光眼发病机制中的作用
Int J Mol Sci. 2024 Feb 15;25(4):2307. doi: 10.3390/ijms25042307.
4
Structural biology of complement receptors.补体受体的结构生物学。
Front Immunol. 2023 Sep 11;14:1239146. doi: 10.3389/fimmu.2023.1239146. eCollection 2023.
7
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.靶向补体途径作为肺癌的治疗策略。
Front Immunol. 2019 May 10;10:954. doi: 10.3389/fimmu.2019.00954. eCollection 2019.

本文引用的文献

4
A simple in vitro method for studies on chemotaxis.一种用于趋化性研究的简单体外方法。
Proc Soc Exp Biol Med. 1974 Nov;147(2):471-4. doi: 10.3181/00379727-147-38367.
5
Membrane receptors.膜受体
Annu Rev Biochem. 1974;43(0):169-214. doi: 10.1146/annurev.bi.43.070174.001125.
10
Complement.补体
Annu Rev Biochem. 1975;44:697-724. doi: 10.1146/annurev.bi.44.070175.003405.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验